Intuitive Surgical (NASDAQ:ISRG) Stock Price Down 0% – Here’s Why

Intuitive Surgical, Inc. (NASDAQ:ISRG) traded down 0% during trading on Wednesday . The company traded as low as $596.47 and last traded at $600.85. 217,390 shares changed hands during mid-day trading, a decline of 87% from the average session volume of 1,703,730 shares. The stock had previously closed at $600.89.

Analyst Ratings Changes

Several brokerages have weighed in on ISRG. Wells Fargo & Company increased their target price on shares of Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Jefferies Financial Group increased their price objective on shares of Intuitive Surgical from $475.00 to $575.00 in a research report on Monday, January 27th. Piper Sandler reissued an “overweight” rating and issued a $670.00 target price (up previously from $538.00) on shares of Intuitive Surgical in a research report on Friday, January 24th. JPMorgan Chase & Co. raised their price target on Intuitive Surgical from $575.00 to $675.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, Stifel Nicolaus lifted their price objective on Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $613.10.

Intuitive Surgical Stock Performance

The company has a market cap of $215.11 billion, a price-to-earnings ratio of 94.22, a price-to-earnings-growth ratio of 5.74 and a beta of 1.39. The business has a 50-day simple moving average of $561.88 and a 200-day simple moving average of $522.27.

Insider Buying and Selling at Intuitive Surgical

In other news, EVP Myriam Curet sold 408 shares of the firm’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $589.75, for a total transaction of $240,618.00. Following the sale, the executive vice president now owns 353 shares of the company’s stock, valued at approximately $208,181.75. This trade represents a 53.61 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Robert Desantis sold 376 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $539.00, for a total value of $202,664.00. Following the sale, the executive vice president now directly owns 5,506 shares in the company, valued at $2,967,734. This trade represents a 6.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,348 shares of company stock valued at $3,587,582 in the last quarter. Corporate insiders own 0.80% of the company’s stock.

Institutional Investors Weigh In On Intuitive Surgical

Several hedge funds and other institutional investors have recently made changes to their positions in ISRG. Atala Financial Inc acquired a new stake in shares of Intuitive Surgical during the 4th quarter worth about $25,000. Berbice Capital Management LLC acquired a new stake in shares of Intuitive Surgical during the 4th quarter worth about $26,000. Parvin Asset Management LLC purchased a new position in Intuitive Surgical during the 4th quarter worth approximately $26,000. BankPlus Trust Department purchased a new position in Intuitive Surgical during the 4th quarter worth approximately $28,000. Finally, Hurley Capital LLC purchased a new position in Intuitive Surgical during the 4th quarter worth approximately $28,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.